Novo Nordisk’s once-daily GLP-1 tablet reduced major adverse cardiovascular events in high-risk adults, including those without prior heart attack or stroke.
Concomitant and bismuth quadruple regimens cleared ~90% of patients and outperformed triple therapy; sequential achieved ~84%. Adherence remained ~97% despite higher but manageable side effects.
Mount Sinai's newly launched Institute for Liver Research has funded its first two pilot projects, chosen from among 11 applications submitted by basic, translational, or clinical research teams, and awarded one-year grants of $30,000 each in hopes of generating preliminary data sufficient to stimulate broader funding and research collaborations. One project focuses on genomics and genetic sequencing of patients to determine how many and which abnormalities are linked to liver disease, while the other proposes to develop a lipid nanoparticle platform for hepatic stellate cell-specific drug delivery.
Mount Sinai New York
Daily News
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
Thank you for signing up for the Daily News alerts. You will begin receiving them shortly.